IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

被引：0
|
作者：
Thomas, Daniel [1 ]
Nakauchi, Yusuke [2 ]
Wu, Manhong [3 ]
Zheng, Ming [3 ]
Sinha, Subarna [4 ]
Dill, David [5 ]
Peltz, Gary [3 ]
Majeti, Ravindra [2 ]
机构：
[1] Stanford Univ, Div Hematol, Dept Med, Stanford, CA 94305 USA
[2] Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA
[3] Stanford Univ, Anesthesia, Stanford, CA 94305 USA
[4] Stanford Res Inst, Menlo Pk, CA USA
[5] Stanford Univ, Comp Sci, Stanford, CA 94305 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-115040
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
440
引用
收藏
页数：2
相关论文
共 46 条
  • [1] Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice
    Kadiyala, Padma
    Carney, Stephen, V
    Gauss, Jessica C.
    Garcia-Fabiani, Maria B.
    Haase, Santiago
    Alghamri, Mahmoud S.
    Nunez, Felipe J.
    Liu, Yayuan
    Yu, Minzhi
    Taher, Ayman
    Nunez, Fernando M.
    Li, Dan
    Edwards, Marta B.
    Kleer, Celina G.
    Appelman, Henry
    Sun, Yilun
    Zhao, Lili
    Moon, James J.
    Schwendeman, Anna
    Lowenstein, Pedro R.
    Castro, Maria G.
    JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (04):
  • [2] The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
    Tian-Xiang Wang
    Jun-Yun Liang
    Cheng Zhang
    Yue Xiong
    Kun-Liang Guan
    Hai-Xin Yuan
    Cell Death & Disease, 10
  • [3] The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
    Wang, Tian-Xiang
    Liang, Jun-Yun
    Zhang, Cheng
    Xiong, Yue
    Guan, Kun-Liang
    Yuan, Hai-Xin
    CELL DEATH & DISEASE, 2019, 10 (10)
  • [4] Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism
    Rendina, Alan R.
    Pietrak, Beth
    Smallwood, Angela
    Zhao, Huizhen
    Qi, Hongwei
    Quinn, Chad
    Adams, Nicholas D.
    Concha, Nestor
    Duraiswami, Chaya
    Thrall, Sara H.
    Sweitzer, Sharon
    Schwartz, Benjamin
    BIOCHEMISTRY, 2013, 52 (26) : 4563 - 4577
  • [5] In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors
    Salamanca-Cardona, Lucia
    Shah, Hardik
    Poot, Alex J.
    Correa, Fabian M.
    Di Gialleonardo, Valentina
    Lui, Hui
    Miloushev, Vesselin Z.
    Granlund, Kristin L.
    Tee, Sui S.
    Cross, Justin R.
    Thompson, Craig B.
    Keshari, Kayvan R.
    CELL METABOLISM, 2017, 26 (06) : 830 - +
  • [6] ACCUMULATION OF 2-HYDROXYGLUTARATE (2-HG) IN NORMAL KARYOTYPE AML PATIENTS WITH IDH1 MUTATION
    Ghazaly, E.
    Smith, P.
    Quentmeier, H.
    Drexler, H.
    Iqbal, S.
    Taussig, D.
    Young, B.
    Lister, A.
    Joel, S.
    Fitzgibbon, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 20 - 20
  • [7] Signaling Pathways of Mutant IDH1 Independent of R-2-Hydroxyglutarate
    Gupta, Charu
    Cruz, Michelle Maria Araujo
    Jyotsana, Nidhi
    Sharma, Amit
    Goparaju, Ramya
    Goerlich, Kerstin
    Schottmann, Renate
    Struys, Eduard
    Jansen, Erwin E.
    Thol, Felicitas
    Ganser, Arnold
    Heuser, Michael
    Chaturvedi, Anuhar
    BLOOD, 2018, 132
  • [8] PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors
    Gbyli, Rana
    Song, Yuanbin
    Liu, Wei
    Gao, Yimeng
    Chandhok, Namrata S.
    Fu, Xiaoying
    Wang, Xiaman
    Patel, Amisha
    Sundaram, Ranjini
    Tebaldi, Toma
    Biancon, Giulia
    Ardasheva, Anastasia
    Qin, Ashley
    Sadykov, Mukhtar
    Mamillapalli, Padmavathi
    Flavell, Richard
    Prebet, Thomas
    Bindra, Ranjit
    Halene, Stephanie
    BLOOD, 2019, 134
  • [9] DETECTION OF GLUTAMATE WITH 2-HYDROXYGLUTARATE IN MAGNETIC RESONANCE SPECTROSCOPY FOR DIAGNOSING IDH1 MUTANT GLIOMA
    Tanaka, K.
    Nagashima, H.
    Sasayama, T.
    Satoh, N.
    Irino, Y.
    Kohmura, E.
    NEURO-ONCOLOGY, 2016, 18 : 9 - 9
  • [10] Outcomes of IDH1/2 mutant AML patients treated with IDH1/2 inhibitors: A single institutional experience.
    Logothetis, Constantine Nick
    Talati, Chetasi
    Calon, Gregoire
    Horvat, Nathan P.
    Volpe, Virginia Olivia
    Vincelette, Nicole D.
    Kuykendall, Andrew T.
    Chan, Onyee
    Sallman, David Andrew
    Padron, Eric
    Sweet, Kendra L.
    Komrokji, Rami S.
    Zhang, Ling
    Lancet, Jeffrey E.
    Yun, Seongseok
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345